NEJM Phase 3 trial data: What is the long-term protection of the new crown vaccine against the Delta strain?

A few days ago, the New England Journal of Medicine (NEJM) recently published a study on the protection of the new crown vaccine against the Delta strain

The analysis of the data of nearly 25,000 people in the phase 3 trial of the mRNA-1273 new crown vaccine shows that the Delta virus of the newly vaccinated (December 2020-April 2021) population compared to the earliest vaccinated (July-December 2020) population The morbidity and severe disease rate after infection of the strain is lower

This result supports that the new crown vaccine still has good protection against the Delta strain, and also provides a reference for the long-term changes in the vaccine's effect

Specifically, this analysis benefited from the timely adjustment of the Phase 3 test plan

In the COVE trial, 14,746 people who were originally in the vaccine group were classified as group e (July-December 2020); 11,431 people who were initially assigned to the placebo group and received the same vaccine during the open label period were classified as group p ( Vaccination from December 2020 to April 2021)

Until June 2021, all the vaccinated persons had few infections, and the incidence of COVID-19 was similar in the two groups of people who were vaccinated at different times (9.

With the prevalence of the Delta strain, the number of cases increased significantly in July and August

In these two months, the incidence of COVID-19 in the newly vaccinated group p was significantly lower by 36.

In the case of newly vaccinated people, the incidence of COVID-19 has decreased more significantly among people 18 to <65 years old

The paper finally pointed out that the study also has certain limitations.

In the NEJM editorial podcast at the same time, NEJM Editor-in-Chief Dr.

Reference

[1] Lindsey R.